Search

Search Constraints

You searched for: Author/Creator Perrone, Francesco

Search Results

1. 2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22. (20th October 2022)

2. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial. (June 2017)

3. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). Issue 1 (December 2016)

4. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). Issue 1 (December 2016)

5. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Issue 4 (April 2018)

6. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. (September 2019)

7. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. (May 2021)

8. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Issue 10 (October 2013)

9. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. (January 2016)

10. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. Issue 12 (10th December 2019)